Antithrombotic therapy in the elderly

Journal of the American College of Cardiology

Volumn 56, Issue 21, 2010, Pages 1683-1692

  Capodanno, Davide ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

bleeding; coagulation; elderly; platelet; thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGING; ANGIOPLASTY; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

AGE FACTORS; AGED; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL ISCHEMIA; RISK FACTORS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 78349301230     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.04.063     Document Type: Review

References (81)

1. H.C. Kung, D.L. Hoyert, J. Xu, and S.L. Murphy Division of Vital Statistics. Deaths: final data for 2005. National vital statistics reports Natl Vital Stat Rep 56 2008 1 120
2. G.F. Anderson, and P.S. Hussey Population aging: a comparison among industrialized countries Health Aff 19 2000 191 203
3. M. Franchini Hemostasis and aging Crit Rev Oncol Hematol 60 2006 144 151
4. E.J. Bastyr 3rd, M.M. Kadrofske, and A.I. Vinik Platelet activity and phosphoinositide turnover increase with advancing age Am J Med 88 1990 601 606
5. R.P. Brandes, I. Fleming, and R. Busse Endothelial aging Cardiovasc Res 66 2005 286 294
6. J. Loscalzo Nitric oxide insufficiency, platelet activation, and arterial thrombosis Circ Res 88 2001 756 762
7. J. Zahavi, N.A. Jones, J. Leyton, M. Dubiel, and V.V. Kakkar Enhanced in vivo platelet "release reaction" in old healthy individuals Thromb Res 17 1980 329 336 (Pubitemid 10129021)
8. K. Turnheim When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly Exp Gerontol 38 2003 843 853
9. A.H. Skolnick, K.P. Alexander, and A.Y. Chen Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative J Am Coll Cardiol 49 2007 1790 1797
10. GRACE Investigators Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes Am Heart J 141 2001 190 199
11. K.P. Alexander, A.Y. Chen, and M.T. Roe Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 294 2005 3108 3116
12. J.E. Nascitz, D. Yeshurun, and M. Odeh Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease Am J Gastroenterol 85 1990 408 411
13. R. Segal, E. Lubart, and A. Leibovitz Early and late effects of low-dose aspirin on renal function in elderly patients Am J Med 115 2003 462 466
14. T.A. Pearson, S.N. Blair, and S.R. Daniels AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases Circulation 106 2002 388 391
15. T. Wolff, T. Miller, and S. Ko Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 150 2009 405 410
16. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
17. C.L. Campbell, S. Smyth, G. Montalescot, and S.R. Steinhubl Aspirin dose for the prevention of cardiovascular disease: a systematic review JAMA 297 2007 2018 2024 (Pubitemid 46740354)
18. T.D. Fraker Jr., S.D. Fihn, and R.J. Gibbons 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina J Am Coll Cardiol 50 2007 2264 2274
19. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) J Am Coll Cardiol 50 2007 e1 e157
20. F.G. Kushner, M. Hand, and S.C. Smith 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
21. R.S. Stafford Aspirin use is low among United States outpatients with coronary artery disease Circulation 101 2000 1097 1101
22. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 47 2006 2130 2139 (Pubitemid 44275145)
23. M.E. Bertrand, H.J. Rupprecht, P. Urban, A.H. Gershlick CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629
24. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
25. S.R. Mehta, S. Yusuf, R.J. Peters Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
26. A. Budaj, S. Yusuf, S.R. Mehta Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups Circulation 106 2002 1622 1626
27. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITONTIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
28. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1 13
29. G. Guagliumi, G.W. Stone, and D.A. Cox Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial Circulation 110 2004 1598 1604 (Pubitemid 39297982)
30. G. Ndrepea, A. Kastrati, and J. Mehilli Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions Circulation 114 2006 2040 2046
31. D. Hasdai, D.R. Holmes Jr., D.A. Criger, E.J. Topol, R.M. Califf, and R.A. Harrington Age and outcome after acute coronary syndromes without persistent ST-segment elevation Am Heart J 139 2000 858 866
32. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo controlled trial (published correction appears in Lancet 2001;357:1370) Lancet 356 2000 2037 2044
33. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina N Engl J Med 338 1998 1498 1505
34. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable SignsSymptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
35. E. Boersma, R.A. Harrington, and D.J. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198
36. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group Low-molecular-weight heparin during instability in coronary artery disease Lancet 347 1996 561 568
37. H.M. Krumholz, J. Hennen, and P.M. Ridker Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly J Am Coll Cardiol 31 1998 973 979
38. M.A. Blazing, J.A. de Lemos, H.D. White A to Z Investigators Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial JAMA 292 2004 55 64
39. R.D. Lopes, K.P. Alexander, and G. Marcucci Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Eur Heart J 29 2008 1827 1833
40. R.D. Lopes, K.P. Alexander, and S.V. Manoukian Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol 53 2009 1021 1030
41. G. Lemesle, L. Bonello, and A. De Labriolle Impact of bivalirudin use on outcomes in nonagenarians undergoing percutaneous coronary intervention J Interv Cardiol 22 2009 61 67
42. J.R. Bartholomew, C.E. Pietrangeli, and M.J. Hursting Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients Drugs Aging 24 2007 489 499
43. L.M. Guzzi, D.A. McCollum, and M.J. Hursting Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia J Thromb Thrombolysis 22 2006 169 176
44. S. Yusuf, S.R. Mehta, and S. Chrolavicius Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
45. K.A. Fox, J.P. Bassand, S.R. Mehta OASIS 5 Investigators Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes Ann Intern Med 147 2007 304 310
46. J. Hirsh, G. Guyatt, G.W. Albers, R. Harrington, H.J. Schunemann American College of Chest Physicians Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 Suppl 2008 71S 105S
47. S. Goto, D.L. Bhatt, and J. Rther Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis Am Heart J 156 2008 855 863
48. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
49. S. Schulman, R.J. Beyth, C. Kearon, and M.N. Levine Hemorrhagic complications of anticoagulant and thrombolytic treatment Chest 133 2008 257S 298S
50. E.M. Hyleck, C. Evans-Molina, C. Shea, L.E. Henault, and S. Regan Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696
51. B.F. Gage, E. Birman-Deych, R. Kerzner, M.J. Radford, D.S. Nilasena, and M.W. Rich Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall Am J Med 118 2005 612 617
52. The Stroke Prevention in Atrial Fibrillation Investigators Bleeding during antithrombotic therapy in patients with atrial fibrillation Arch Intern Med 156 1996 409 416
53. R.J. Beyth Hemorrhagic complications of oral anticoagulant therapy Clin Geriatr Med 17 2001 49 56
54. J. Mant, F.D. Hobbs, and K. Fletcher Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
55. D. Garcia, S. Regan, and M. Crowther Warfarin maintenance dosing patterns in clinical practice Chest 127 2005 2049 2056
56. M. Redwood, C. Taylor, and B.J. Bain The association of age with dosage requirement for warfarin Age Ageing 20 1991 217 220
57. J.H. Gurwitz, J. Avorn, and D. Ross-Degnan Aging and the anticoagulant response to warfarin therapy Ann Intern Med 116 1992 901 904
58. T.E. Klein, R.B. Altman, and N. Eriksson Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 2009 753 764
59. M.B. O'Connell, P.R. Kowal, and C.J. Allivato Evaluation of warfarin initiation regimens in elderly patients Pharmacotherapy 20 2000 923 930
60. D. McCormick, J.H. Gurwitz, and J. Goldberg Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use J Thromb Thrombolysis 7 1999 157 163
61. F. Marn, R. Gonzlez-Conejero, and P. Capranzano Pharmacogenetics in cardiovascular antithrombotic therapy J Am Coll Cardiol 54 2009 1041 1057
62. R.J. Beyth, L.M. Quinn, and C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 1998 91 99
63. P.M. Kuijer, B.A. Hutten, M.H. Prins, and H.R. Bller Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism Arch Intern Med 159 1999 457 460
64. T.I. Shireman, J.D. Mahnken, P.A. Howard, T.F. Kresowik, Q. Hou, and E.F. Ellerbeck Development of a contemporary bleeding risk model for elderly warfarin recipients Chest 130 2006 1390 1396
65. B.F. Gage, Y. Yan, and P.E. Milligan Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 2006 713 719
66. S.J. Mattichack, P.S. Reed, and M.J. Gallagher Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction J Interv Cardiol 18 2005 163 166
67. Z. Khurram, E. Chou, and R. Minutello Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding J Invasive Cardiol 18 2006 162 164
68. K. Buresly, M.J. Eisenberg, X. Zhang, and L. Pilote Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction Arch Intern Med 165 2005 784 789
69. S.J. Connolly, M.D. Ezekowitz, S. Yusuf RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
70. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients Lancet 343 1994 311 322
71. H.D. White, G.I. Barbash, and R.M. Califf Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial Circulation 94 1996 1826 1833
72. G.W. Stone, C.L. Grines, and K.F. Browne Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial J Am Coll Cardiol 25 1995 370 377
73. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction N Engl J Med 336 1997 1621 1628
74. H.R. Andersen, T.T. Nielsen, K. Rasmussen DANAMI-2 Investigators A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction N Engl J Med 349 2003 733 742
75. J.J. Thune, D.E. Hoefsten, M.G. Lindholm Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI)-2 Investigators Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty Circulation 112 2005 2017 2021
76. Z.M. Chen, L.X. Jiang, Y.P. Chen COMMIT Investigators Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621 (Pubitemid 41552416)
77. M.S. Sabatine, C.P. Cannon, C.M. Gibson CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
78. J.P. Curtis, J.H. Alexander, Y. Huang ASSENT-2 and ASSENT-3 Investigators Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3) Am J Cardiol 94 2004 279 283
79. H.D. White, E. Braunwald, and S.A. Murphy Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25 Eur Heart J 28 2007 1066 1071
80. S. Savonitto, P.W. Armstrong, and A.M. Lincoff Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: dichotomous response as a function of age in the GUSTO V trial Eur Heart J 24 2003 1807 1814
81. P.W. Armstrong, W.C. Chang, L. Wallentin ASSENT-3 and ASSENT-3 PLUS Investigators Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data CMAJ 174 2006 1421 1426